Journal
CLINICAL CHEMISTRY
Volume 68, Issue 1, Pages 204-213Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/clinchem/hvab216
Keywords
-
Categories
Funding
- National Center for Advancing Translational Sciences, National Institutes of Health [UL1 TR001085]
- NIH/NIAID [R01AI127877, R01AI130398]
- NIH [1U54CA260517]
- Coulter COVID-19 Rapid Response Award
- Crown Family Foundation
Ask authors/readers for more resources
This study found that the concentration of nucleocapsid antigen in plasma is associated with the severity of COVID-19, particularly with ICU admission. Antigenemia showed comparable diagnostic performance to upper respiratory NAAT, aiding in triaging patients for optimized intensive care utilization.
BACKGROUND: Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid antigen in blood has been described, but the diagnostic and prognostic role of antigenemia is not well understood. This study aimed to determine the frequency, duration, and concentration of nucleocapsid antigen in plasma and its association with coronavirus disease 2019 (COVID-19) severity. METHODS: We utilized an ultrasensitive electrochemilu-minescence immunoassay targeting SARS-CoV-2 nucleocapsid antigen to evaluate 777 plasma samples from 104 individuals with COVID-19. We compared plasma antigen to respiratory nucleic acid amplification testing (NAAT) in 74 individuals with COVID-19 from samples collected 61 day of diagnostic respiratory NAAT and in 52 SARS-CoV-2-negative individuals. We used Kruskal-Wallis tests, multivariable logistic regression, and mixed-effects modeling to evaluate whether plasma antigen concentration was associated with disease severity. RESULTS: Plasma antigen had 91.9% (95% CI 83.2%-97.0%) clinical sensitivity and 94.2% (84.1%-98.8%) clinical specificity. Antigen-negative plasma samples belonged to patients with later respiratory cycle thresholds (C-t) when compared with antigen-positive plasma samples. Median plasma antigen concentration (log(10) fg/mL) was 5.4 (interquartile range 3.9-6.0) in outpatients, 6.0 (5.4-6.5) in inpatients, and 6.6 (6.1-7.2) in intensive care unit (ICU) patients. In models adjusted for age, sex, diabetes, and hypertension, plasma antigen concentration at diagnosis was associated with ICU admission [odds ratio 2.8 (95% CI 1.2-6.2), P=.01] but not with non-ICU hospitalization. Rate of antigen decrease was not associated with disease severity. CONCLUSIONS: SARS-CoV-2 plasma nucleocapsid antigen exhibited comparable diagnostic performance to upper respiratory NAAT, especially among those with late respiratory Ct. In addition to currently available tools, antigenemia may facilitate patient triage to optimize intensive care utilization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available